For the third quarter of FY March 2026, net sales were 30,353 million yen, a 17.3% increase year-over-year. Operating income turned positive to 427 million yen. Full-year earnings guidance was revised to net sales of 39,500 million yen and operating income of 400 million yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4552","jir_company_name":"JCR Pharmaceuticals Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-01-28","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/4552-20260128-03.pdf","jir_short_summary":"For the third quarter of FY March 2026, net sales were 30,353 million yen, a 17.3% increase year-over-year. Operating income turned positive to 427 million yen. Full-year earnings guidance was revised to net sales of 39,500 million yen and operating income of 400 million yen.","jir_summary":"### Performance Overview\nFor the third quarter of FY March 2026, consolidated net sales increased 17.3% year-over-year to 30,353 million yen. Gross profit rose 25.0% to 23,585 million yen. Operating income turned positive to 427 million yen, aided also by foreign exchange gains recorded as non-operating income. R&D expenses increased 34.7% due to recognition of contract upfront payments. Extraordinary profit rose 96.4% due to the recording of subsidy income. Net income attributable to owners of parent for the quarter was 1,744 million yen, marking a significant improvement from a loss in the same period last year.\n\n### Revision of Full-year Earnings Forecast and Outlook\nThe full-year consolidated earnings forecast was revised upward for net sales to 39,500 million yen but downward for operating income by 2,200 million yen to 400 million yen. The downward revision in operating income reflects increased cost of sales and selling, general and administrative expenses. R&D expenses were revised upward by 1,500 million yen due to contract upfront payments related to obtaining exclusive licenses. Net sales growth is expected to be driven by increased demand for renal anemia and Fabry disease treatments. Going forward, the company will focus on the development and commercialization of the new therapeutic agent Givinostat and aims to expand its portfolio of rare disease treatments.","jir_financial_highlights":"Net Sales: 30,353 million yen (Year-over-Year +17.3%)\nOperating Income: 427 million yen (Turned positive from loss year-over-year (previous period was -754 million yen))\nNet Income Attributable to Owners of Parent (Quarter): 1,744 million yen (Increased year-over-year (previous period was -576 million yen))\nR&D Expenses: 13,372 million yen (Year-over-Year +34.7%)\nFull-year Net Sales Forecast: 39,500 million yen (Up 4.5% from previous forecast)\nFull-year Operating Income Forecast: 400 million yen (Down 84.6% from previous forecast)","jir_category":"","jir_hashtags":"#JCRPharmaceuticals, #EarningsPresentation, #JapaneseStocks","jir_key_figures":"Net Sales: 30,353 million yen (Year-over-Year +17.3%)\nOperating Income: 427 million yen (Previous period was a loss of -754 million yen)\nNet Income Attributable to Owners of Parent (Quarter): 1,744 million yen (Previous period was a loss of -576 million yen)","jir_meta_title":"JCR Pharmaceuticals FY March 2026 Q3 Results: Net Sales Up 17.3%, Operating Income Turns Positive","jir_meta_description":"JCR Pharmaceuticals reported net sales of 30,353 million yen for FY March 2026 Q3, a 17.3% year-over-year increase, with operating income turning positive to 427 million yen. The full-year earnings forecast was revised upward for net sales to 39,500 million yen.","jir_og_title":"JCR Pharmaceuticals FY 2026 Q3 Earnings Announcement: Net Sales Up 17.3%","jir_og_description":"JCR Pharmaceuticals posted net sales of 30,353 million yen for FY March 2026 Q3, a 17.3% increase year-over-year, with operating income turning positive.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY March 2025 Q3 Cumulative\\\",\\\"FY March 2026 Q3 Cumulative\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[25880,30353],\\\"borderColor\\\":\\\"#4CAF50\\\",\\\"backgroundColor\\\":\\\"rgba(76,175,80,0.2)\\\",\\\"fill\\\":true}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY March 2025 Q3 Cumulative\\\",\\\"FY March 2026 Q3 Cumulative\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[-754,427],\\\"backgroundColor\\\":[\\\"#F44336\\\",\\\"#4CAF50\\\"]}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent (Quarter) Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY March 2025 Q3 Cumulative\\\",\\\"FY March 2026 Q3 Cumulative\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[-576,1744],\\\"borderColor\\\":\\\"#2196F3\\\",\\\"backgroundColor\\\":\\\"rgba(33,150,243,0.2)\\\",\\\"fill\\\":true}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Net Sales Breakdown (FY March 2026 Q3 Cumulative)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Growject\u00ae\\\",\\\"Isucargo\u00ae\\\",\\\"Temcell\u00ae HS Injection\\\",\\\"Renal Anemia Treatments\\\",\\\"Epoetin Alfa BS Injection 'JCR'\\\",\\\"Darbepoetin Alfa BS Injection 'JCR'\\\",\\\"Agalsidase Beta BS IV Infusion 'JCR'\\\",\\\"Contract Revenue\\\",\\\"Others\\\"],\\\"datasets\\\":[{\\\"data\\\":[13539,5179,2212,2346,595,1750,863,5249,961],\\\"backgroundColor\\\":[\\\"#4CAF50\\\",\\\"#FFC107\\\",\\\"#03A9F4\\\",\\\"#E91E63\\\",\\\"#9C27B0\\\",\\\"#FF5722\\\",\\\"#795548\\\",\\\"#00BCD4\\\",\\\"#8BC34A\\\"]}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"right\\\"}}}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Full-year Earnings Guidance Comparison (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Net Sales\\\",\\\"Operating Income\\\",\\\"Ordinary Income\\\",\\\"Net Income Attributable to Owners of Parent\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Previous Forecast\\\",\\\"data\\\":[37800,2600,2400,3000],\\\"backgroundColor\\\":\\\"#9E9E9E\\\"},{\\\"label\\\":\\\"Revised Forecast\\\",\\\"data\\\":[39500,400,400,1600],\\\"backgroundColor\\\":\\\"#4CAF50\\\"}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":9680,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-21427","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n